GLP-1 Inhibitors May Reduce Stroke Risks and Improve Recovery, Research Indicates

New research suggests that weight loss medications, particularly GLP-1 inhibitors such as semaglutide (Ozempic), may play a significant role in preventing strokes and mitigating complications associated with brain injuries. These findings were presented at the Society of NeuroInterventional Surgery's recent annual meeting, where three studies explored the impact of these medications on stroke outcomes.

The first study analyzed data from the University of Wisconsin-Madison and a global health collaborative, focusing on the effects of Ozempic on patients who had suffered an acute ischemic stroke. The analysis included over two million patients, revealing that those on Ozempic had a markedly lower mortality rate from strokes compared to non-users. Specifically, the data showed a mortality rate of 5.26% among Ozempic users versus 21.61% for non-users. Additionally, long-term survival rates post-stroke were significantly higher in those using the medication.

The second study from the same institution examined emergency department records to assess the correlation between Ozempic usage and stroke incidence. The findings indicated that potential Ozempic users exhibited a significantly reduced likelihood of experiencing a stroke. Researchers recommend further investigation into pharmacy data to refine these associations.

The third study, conducted by researchers at the University of Texas Medical Branch, investigated the effects of GLP-1 inhibitors on patient outcomes following brain hemorrhages and strokes. The research found that users of these medications had a lower risk of cognitive side effects, seizures, and further hemorrhages, as well as improved survival rates after such incidents.

Dr. Ahmed Elbayomy, a research fellow involved in two of the studies, noted the promising nature of these findings, suggesting that they could usher in new perspectives on stroke prevention and treatment strategies. Dr. Matias Costa from the University of Texas Medical Branch echoed this sentiment, emphasizing the potential for GLP-1 inhibitors to mitigate the severe impacts of strokes and associated brain injuries.

As this research unfolds, the medical community is encouraged to explore the implications of GLP-1 inhibitors further, particularly in the context of stroke prevention and recovery.